StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN)

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, August 23rd.

Evogene Price Performance

NASDAQ EVGN opened at $1.97 on Friday. The business’s 50-day moving average is $2.71 and its 200 day moving average is $4.87. Evogene has a 1 year low of $1.89 and a 1 year high of $10.40.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%. The firm had revenue of $0.91 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.